Free Trial

TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics logo
$35.07 +0.52 (+1.51%)
(As of 11/22/2024 ET)

TG Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
5

Based on 6 Wall Street analysts who have issued ratings for TG Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for TGTX.

Consensus Price Target

$37.67
7.40% Upside
According to the 6 analysts' twelve-month price targets for TG Therapeutics, the average price target is $37.67. The highest price target for TGTX is $55.00, while the lowest price target for TGTX is $22.00. The average price target represents a forecasted upside of 7.40% from the current price of $35.07.
Get the Latest News and Ratings for TGTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for TG Therapeutics and its competitors.

Sign Up

TGTX Analyst Ratings Over Time

TypeCurrent Forecast
11/25/23 to 11/24/24
1 Month Ago
10/26/23 to 10/25/24
3 Months Ago
8/27/23 to 8/26/24
1 Year Ago
11/25/22 to 11/25/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$37.67$31.83$31.83$22.25
Forecasted Upside7.40% Upside36.27% Upside32.80% Upside73.96% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

TGTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TGTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

TG Therapeutics Stock vs. The Competition

TypeTG TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.40% Upside27,073.48% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent TGTX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024HC Wainwright
2 of 5 stars
 Boost TargetBuy ➝ Buy$49.00 ➝ $55.00+121.06%
11/5/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$20.00 ➝ $22.00-10.06%
10/29/2024TD Cowen
4 of 5 stars
T. Bancroft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00+105.34%
8/7/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$29.00 ➝ $34.00+61.44%
5/2/2024LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$39.00 ➝ $40.00+151.89%
4/18/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$25.00+75.93%
9 hidden AI stocks set to thrive in Trump’s new era (Ad)

AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)

Get the Name of These AI Picks Now
11/1/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$23.00+106.65%
4/17/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$24.00+16.90%
1/24/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$16.00 ➝ $25.00+89.54%
12/29/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform$5.00 ➝ $6.00-40.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:30 AM ET.


TGTX Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for TG Therapeutics is $37.67, with a high forecast of $55.00 and a low forecast of $22.00.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TGTX shares.

According to analysts, TG Therapeutics's stock has a predicted upside of 7.40% based on their 12-month stock forecasts.

TG Therapeutics has been rated by research analysts at HC Wainwright, TD Cowen, and The Goldman Sachs Group in the past 90 days.

Analysts like TG Therapeutics more than other "medical" companies. The consensus rating score for TG Therapeutics is 2.83 while the average consensus rating score for "medical" companies is 2.80. Learn more on how TGTX compares to other companies.


This page (NASDAQ:TGTX) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners